DR info

臨床試験数 : 15 / 薬物数 : 24 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 105

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Bleomycin + Fibrovein
   Oslo University Hospital
      2011   Phase 4   NCT01347294   Norway;
Bleomycin Baxter
   Department of Radiology, Oslo University Hospital, Norway
      2011   -   EUCTR2011-001455-37-NO   Norway;
Dehydrated Alcohol (Absolute Alcohol) BP for Injection
   ORFAGEN
      2009   -   EUCTR2009-011276-29-FR   France;
ETHANOL (96 PER CENT)
   ORFAGEN
      2009   -   EUCTR2009-011276-29-FR   France;
ETHANOL BP
   ORFAGEN
      2009   -   EUCTR2009-011276-29-FR   France;
Ethanol
   Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
      2015   Phase 1 study   ChiCTR-OIB-15007455   China;
Ethanol Gel
   Orfagen
      2007   Phase 2   NCT00462462   France;United States;
Ethanol Solution
   Orfagen
      2007   Phase 2   NCT00462462   France;United States;
Ethanol gel
   ORFAGEN
      2009   -   EUCTR2009-011276-29-FR   France;
Ethanol-amine Oleate Sclerotherapy Injection
   Suez Canal University
      2019   -   NCT04930952   Egypt;
Ethanolamine oleate
   Danjo Atsushi
      2009   Phase 2   JPRN-jRCTs071180067   Japan;
   Nomura Tadashi
      2021   Phase 3   JPRN-jRCT2051200046   Japan;
Fibrovein
   Department of Radiology, Oslo University Hospital, Norway
      2011   -   EUCTR2011-001455-37-NO   Norway;
Iopamiron
   Danjo Atsushi
      2009   Phase 2   JPRN-jRCTs071180067   Japan;
L0122
   ORFAGEN
      2009   -   EUCTR2009-011276-29-FR   France;
Polidocanol
   Uka Mayu
      2020   -   JPRN-jRCTs061200036   Japan;
Rapamycin
   Peking Union Medical College Hospital
      2018   Phase 4   NCT03767660   China;
Sirolimus
   Children's Hospital Medical Center, Cincinnati
      2009   Phase 2   NCT00975819   United States;
   Medical University of South Carolina
      2021   Phase 2   NCT04861064   United States;
Trametinib tablet
   Stanford University
      2020   Phase 2   NCT04258046   United States;
VT30
   Venthera, Inc., a BridgeBio company
      2020   Phase 1/Phase 2   NCT04409145   United States;